Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 493

1.

Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration.

Abo Y, Zannou Djimon M, Messou E, Balestre E, Kouakou M, Akakpo J, Ahouada C, de Rekeneire N, Dabis F, Lewden C, Minga A; IeDEA West Africa Collaboration.

BMC Infect Dis. 2015 Apr 9;15(1):176. doi: 10.1186/s12879-015-0910-3.

2.

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.

Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group.

Eur J Prev Cardiol. 2015 Apr 16. pii: 2047487315579291. [Epub ahead of print]

PMID:
25882821
3.

Barriers to antiretroviral treatment initiation in rural KwaZulu-Natal, South Africa.

Plazy M, Newell ML, Orne-Gliemann J, Naidu K, Dabis F, Dray-Spira R.

HIV Med. 2015 Apr 8. doi: 10.1111/hiv.12253. [Epub ahead of print]

PMID:
25857535
4.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group.

Clin Infect Dis. 2015 Mar 16. pii: civ217. [Epub ahead of print]

PMID:
25778750
5.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; the ESCMID European Study Group on Viral Hepatitis.

Liver Int. 2015 Feb 4. doi: 10.1111/liv.12799. [Epub ahead of print]

PMID:
25650873
6.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

PMID:
25567330
7.

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F; Canadian−European Clade Collaboration.

CMAJ Open. 2014 Oct 1;2(4):E318-29. doi: 10.9778/cmajo.20140017. eCollection 2014 Oct.

8.

Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.

Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N.

AIDS. 2015 Jan 14;29(2):221-9. doi: 10.1097/QAD.0000000000000540.

9.

Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, de Wit S, Dabis F, Pradier C, Monforte Ad, Rickenbach M, Law M, Lundgren J, Sabin C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19516. doi: 10.7448/IAS.17.4.19516. eCollection 2014.

10.

The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.

Ross E, Tanser F, Pei P, Newell ML, Losina E, Thiebaut R, Weinstein M, Freedberg K, Anglaret X, Scott C, Dabis F, Walensky R.

HIV Clin Trials. 2014 Sep-Oct;15(5):185-98. doi: 10.1310/hct1505-185.

11.

Factors Associated with HIV Testing History among Pregnant Women and Their Partners in Georgia: The ANRS 12127 Prenahtest Trial.

Butsashvili M, Kajaia M, Kamkamidze G, Tchendjou P, Desgrees du Loû A, Dabis F, Orne-Gliemann J.

AIDS Res Treat. 2014;2014:356090. doi: 10.1155/2014/356090. Epub 2014 Sep 29.

12.

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.

Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J.

AIDS. 2014 Sep 24;28(15):2297-306. doi: 10.1097/QAD.0000000000000410.

PMID:
25313585
13.

Incidence of pregnancy after antiretroviral therapy initiation and associated factors in 8 West African countries.

Burgos-Soto J, Balestre E, Minga A, Ajayi S, Sawadogo A, Zannou MD, Leroy V, Ekouevi DK, Dabis F, Becquet R; IeDEA West Africa Collaboration.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e45-54. doi: 10.1097/QAI.0000000000000279.

PMID:
25216079
14.

Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.

Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA.

PLoS Med. 2014 Sep 9;11(9):e1001718. doi: 10.1371/journal.pmed.1001718. eCollection 2014 Sep.

15.

Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM, Gottlieb GS, Vitoria M, Dabis F, Eholie SP.

BMC Infect Dis. 2014 Aug 26;14:461. doi: 10.1186/1471-2334-14-461. Review.

16.

Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaboration.

Tchounga BK, Inwoley A, Coffie PA, Minta D, Messou E, Bado G, Minga A, Hawerlander D, Kane C, Eholie SP, Dabis F, Ekouevi DK; WADA Collaboration.

J Int AIDS Soc. 2014 Aug 11;17:19064. doi: 10.7448/IAS.17.1.19064. eCollection 2014.

17.

Test and treat all as soon as possible.

Dabis F.

Lancet Glob Health. 2014 Jan;2(1):e2-3. doi: 10.1016/S2214-109X(13)70178-5. Epub 2013 Dec 10. No abstract available.

18.

Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort.

Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group.

PLoS One. 2014 Jul 30;9(7):e102671. doi: 10.1371/journal.pone.0102671. eCollection 2014.

19.

Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France.

Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, Semaille C.

Liver Int. 2015 Jan;35(1):65-70. doi: 10.1111/liv.12639. Epub 2014 Jul 24.

PMID:
25040895
20.

HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.

Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):390-409. doi: 10.1001/jama.2014.7999. Erratum in: JAMA. 2014 Jul 23-30;312(4):403. JAMA. 2014 Aug 13;312(6):652.

PMID:
25038358
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk